Subscribe 600$/product give away!
Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

BIDIL- hydralazine hydrochloride and isosorbide dinitrate tablet, film coated

Patient Information

Patients should be informed of possible side effects and advised to take the medication regularly and continuously as directed.


Inform patients that headaches often accompany treatment with BiDil, especially during initiation of treatment. Advise patients to consult a physician to adjust the dose of BiDil if headache continues with repeated dosing.


Warn patients about lightheadedness on standing.

Advise patients that inadequate fluid intake or excessive fluid loss from perspiration, diarrhea or vomiting may lead to an excessive fall in blood pressure and cause lightheadedness or even syncope. If syncope does occur, advise patients to discontinue BiDil and notify their prescribing physician as soon as possible.

Phosphodiesterase-5 Inhibitors

Advise patients to inform their physicians if they are taking, or planning to take, sildenafil, vardenafil, or tadalafil. Bidil should not be taken concomitantly with phosphodiesterase-5 inhibitors.

Worsening Ischemic Heart Disease

Advise patients to inform their physicians of any worsening of symptoms of myocardial ischemia, especially those with hypertrophic cardiomyopathy.

Systemic Lupus Erythematosus-like Symptoms

Advise patients if symptoms suggestive of systemic lupus erythematosus such as arthralgia, fever, chest pain, prolonged malaise occur to notify their prescribing physician.

Peripheral Neuritis

Advise patients if symptoms of peripheral neuritis paresthesia, numbness, and tingling occur to notify the prescribing physician.

Manufactured for:
Arbor Pharmaceuticals, LLC
Atlanta, GA 30328

Manufactured by:
Kremers Urban Pharmaceuticals Inc.,
a subsidiary of Lannett Company, Inc.
Seymour, IN 47274, USA

BiDil is a registered trademark of Arbor Pharmaceuticals, LLC
U.S. Patent number 6,784,177; 6,465,463
All rights reserved


Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources | Sitemap
2017 © Copyright Questions?
Please contact: